CIRculating Cell-free nUcLeic Acids in Cancer Therapy Monitoring -01
ConditionNext-Generation-Sequencing
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital Tuebingen
About this trial
In cooperation with the molecular tumor board of the University Hospital Tübingen (UKT), a prospective collection of blood samples during the course of therapy is planned. It is a pilot study in which the technical feasibility of the approach (Highly Sensitive Next-Generation Sequencing (NGS) methods) initially should to be evaluated and further developed.
Eligibility criteria
Qualifiers
Age ≥ 18 years
Advanced tumor disease
Ability to consent
Existence of a declaration of consent signed by the patient and physician (informed consent for study participation and Comprehensive Cancer Center (CCC) biobank
Disqualifiers
None
Trial design
Treatments tested in this trial
- Molecular genetic diagnostic
Treatment groups
200 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
University Hospital Tuebingen
Lead sponsor
German Consortium for Translational Cancer Research
Collaborator
Source ClinicalTrials.gov